Home > Report on the risk assessment of methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil) in the framework of the Council Decision on new psychoactive substances.

European Monitoring Centre for Drugs and Drug Addiction. [EMCDDA] (2018) Report on the risk assessment of methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil) in the framework of the Council Decision on new psychoactive substances. Luxembourg: Publications Office of the European Union. 105 p.

[img]
Preview
PDF (Risk assessment carfentanil) - Published Version
1MB

This publication presents the data and findings of the risk assessment on methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place carfentanil in Schedule I and Schedule IV of the Single Convention on Narcotic Drugs of 1961 based on a recommendation by the World Health Organization. This recommendation was substantially supported by European data provided by the EMCDDA.

Carfentanil or carfentanyl is an analog of the synthetic opioid analgesic fentanyl.

Item Type:Evidence resource
Publication Type:Report
Drug Type:New psychoactive substance
Intervention Type:AOD disorder harm reduction
Source:EMCDDA
Date:July 2018
Pages:105 p.
Publisher:Publications Office of the European Union
Corporate Creators:European Monitoring Centre for Drugs and Drug Addiction
Place of Publication:Luxembourg
EndNote:View
Accession Number:HRB (Electronic Only)
Subjects:B Substances > Opioids (opiates) > Opioid product > Fentanyl
B Substances > New (novel) psychoactive substances
VA Geographic area > International aspects

Repository Staff Only: item control page